Art Taveras

Art Taveras

Chief Tech/Sci/R&D Officer at X4 PHARMACEUTICALS, INC.

Net worth: 325 678 $ as of 2024-03-30

60 year
Health Technology
Consumer Services
Commercial Services

Profile

Art Taveras is the founder of Transform Therapeutics, which was founded in 2015.
He held the title of Chief Scientific Officer & Head-Drug Discovery from 2015 to 2020.
Currently, he is the Chief Scientific Officer at X4 Pharmaceuticals, Inc. since 2020.
Dr. Taveras has held several former positions, including Vice President-Drug Discovery & Development at Alantos Pharmaceuticals Holding, Inc. from 2004 to 2007, Vice President-Small Molecule Drug Discovery at Biogen Idec, Inc. (North Carolina) from 2007 to 2013, President & Chief Scientific Officer at Shanghai ChemPartner Co., Ltd.
from 2013 to 2014, and Chief Scientific Officer at Comet Therapeutics, Inc. from 2018 to 2020.
Dr. Taveras received his undergraduate, graduate, and doctorate degrees from Rensselaer Polytechnic Institute.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2024-03-10 234,301 ( 0.14% ) 325 678 $ 2024-03-30

Art Taveras active positions

CompaniesPositionStart
X4 PHARMACEUTICALS, INC. Chief Tech/Sci/R&D Officer 2020-11-01
All active positions of Art Taveras

Former positions of Art Taveras

CompaniesPositionEnd
Transform Therapeutics Founder 2020-10-31
Chief Tech/Sci/R&D Officer 2020-06-30
President 2014-11-30
Corporate Officer/Principal 2012-12-31
Corporate Officer/Principal 2007-10-31
See the detail of Art Taveras's experience

Training of Art Taveras

Rensselaer Polytechnic Institute Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Art Taveras's experience

Connections

45

1st degree connections

7

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
X4 PHARMACEUTICALS, INC.

Health Technology

Private companies5

Health Technology

Health Technology

Commercial Services

Health Technology

Transform Therapeutics

See company connections